DDInter416 DDInter649
This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s. Clotrimazole falls under the _imidazole_ category of _azole_ antifungals, possessing broad-spectrum antimycotic activity. It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets). As well as its antifungal activity, clotrimazole has become a drug of interest in treating several other diseases such as sickle cell disease, malaria and some cancers. The minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as well as athlete's foot.
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.
Clotrimazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Clotrimazole {u} (Compound) causes {v} (Side Effect) Pollakiuria
Pollakiuria {u} (Side Effect) is caused by {v} (Compound) Enzalutamide
Clotrimazole {u} (Compound) resembles {v} (Compound) Sulfinpyrazone
Sulfinpyrazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Clotrimazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bicalutamide
Bicalutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Clotrimazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enzalutamide
Clotrimazole {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Nilutamide
Nilutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Clotrimazole {u} (Compound) causes {v} (Side Effect) Pollakiuria
Pollakiuria {u} (Side Effect) is caused by {v} (Compound) Bicalutamide
Bicalutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Clotrimazole {u} (Compound) resembles {v} (Compound) Sulfinpyrazone
Sulfinpyrazone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Clotrimazole {u} (Compound) resembles {v} (Compound) Darifenacin
Darifenacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bicalutamide
Bicalutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Clotrimazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Clotrimazole (Compound) causes Pollakiuria (Side Effect) and Pollakiuria (Side Effect) is caused by Enzalutamide (Compound)
Clotrimazole (Compound) resembles Sulfinpyrazone (Compound) and Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone may lead to a major life threatening interaction when taken with Enzalutamide
Clotrimazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bicalutamide (Compound) and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Clotrimazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Clotrimazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilutamide (Compound) and Nilutamide (Compound) resembles Enzalutamide (Compound)
Clotrimazole (Compound) causes Pollakiuria (Side Effect) and Pollakiuria (Side Effect) is caused by Bicalutamide (Compound) and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Clotrimazole (Compound) resembles Sulfinpyrazone (Compound) and Sulfinpyrazone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Clotrimazole (Compound) resembles Darifenacin (Compound) and Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)